Recursion Pharmaceuticals Analyst Price Targets

Recursion Pharmaceuticals Inc

RXRXNASDAQ

Trade with Public

$3.46

-0.70-16.71%

Últ. Act.: Oct 16, 7:59 PM

$3.49

-0.67-16.11%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Recursion Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Recursion Pharmaceuticals (RXRX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingOverweight# Analysts7Avg. Consensus PT$8Upside to Avg. PT+123.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 14, 2026	Morgan Stanley	Vikram Purohit	PT Raise	Equal-Weight	$5→$6
May 7, 2026	Needham	Gil Blum	Maintained	Buy	$8
Apr 30, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$11→$10
Feb 26, 2026	B of A Securities	Michael Ryskin	PT Cut	Neutral	$7→$6
Feb 26, 2026	Needham	Gil Blum	Maintained	Buy	$8
Dec 17, 2025	JP Morgan	Eric Joseph	Upgrade	Neutral→Overweight	$10→$11
Sep 11, 2025	Needham	Gil Blum	Maintained	Buy	$8
Jul 8, 2025	Needham	Gil Blum	Maintained	Buy	$8
Jul 3, 2025	Morgan Stanley	Vikram Purohit	Assumes	Equal-Weight	$5
Jun 16, 2025	Morgan Stanley	Vikram Purohit	PT Cut	Equal-Weight	$8→$5
May 6, 2025	Needham	Gil Blum	PT Cut	Buy	$11→$8
Apr 10, 2025	Morgan Stanley	Vikram Purohit	PT Cut	Equal-Weight	$10→$8
Apr 8, 2025	Needham	Gil Blum	Maintained	Buy	$11
Feb 28, 2025	Leerink Partners	Mani Foroohar	PT Cut	Market Perform	$7→$6
Feb 6, 2025	Needham	Gil Blum	Maintained	Buy	$11
Jan 8, 2025	Keybanc	Scott Schoenhaus	PT Cut	Overweight	$12→$10
Dec 11, 2024	Needham	Gil Blum	Maintained	Buy	$11
Nov 20, 2024	Needham	Gil Blum	Maintained	Buy	$11
Nov 7, 2024	Needham	Gil Blum	Maintained	Buy	$11
Sep 4, 2024	Needham	Gil Blum	PT Cut	Buy	$16→$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.

Benzinga Newsdesk

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

Priya Nigam

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

People Also Watch

People Also Watch

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PROJP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PROB of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PROJP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PROB of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target